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Background: In January 2015, the diagnostic and therapeutic criteria for gestational diabetes 
changed, with the goal of increasing the sensitivity of diagnosis and improving overall 
glycaemic control, and thus reducing adverse pregnancy outcomes.   
Aim:  Our primary aim was to evaluate the effect of the new guidelines on the incidence of 
diagnosis of gestational diabetes and the incidence of therapeutic interventions. Our 
secondary aim was to look at the incidence of adverse pregnancy outcomes. 
Materials and Methods: A retrospective clinical audit was conducted at a regional hospital to 
compare the incidence of gestational diabetes, and specific maternal and neonatal outcomes 
before and after the change in guidelines was implemented. Data were collected via chart 
review for a six month period before and after the change in guidelines in January 2015. Data 
collected included demographics, neonatal and maternal outcomes and the treatment type 
used for patients diagnosed with gestational diabetes.  
Results: There was a significant increase in the incidence of diagnosis of gestational diabetes 
(9.8% to 19.6%) p<0.001, and an overall increase in the use of pharmacological treatments 
for gestational diabetes. There was no significant difference in the incidence of the adverse 
outcomes measured, including caesarean delivery and incidence of macrosomia. There was 
no significant change in mean fetal weight.   
Conclusions: Despite a doubling of the incidence of diagnosis of gestational diabetes, and a 
consequent increase in pharmacological interventions, the change in diagnostic and 
therapeutic criteria did not significantly reduce the neonatal or maternal adverse outcomes 
measured.  
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Gestational diabetes mellitus (GDM) is defined as impaired glucose tolerance with its 
onset or first recognition occurring during pregnancy. 1,2 It is relatively common, affecting 
4.6 – 9.6% of pregnancies in Australia prior to 2015.3, 4 GDM is of great clinical significance, 
with associated adverse health outcomes for the mother such as instrumental and caesarean 
delivery5, 6, and for the infant, including macrosomia and neonatal hypoglycaemia.7 - 9 
Increasingly, the long term sequelae of GDM such as development of type 2 diabetes and 
metabolic syndrome are being brought to light.10, 11 Effective treatment of GDM minimises 
the risks of many of these adverse outcomes.12 – 15 It is important that GDM is diagnosed 
early in pregnancy, so that these patients may receive optimal management in order to reduce 
their risk of adverse pregnancy outcomes.  
 
The diagnosis of GDM has been subject to debate. The original diagnostic criteria 
were developed in 1964, and were based on trying to predict the likelihood of the mother 
developing diabetes after pregnancy,16 rather than identifying current diabetes and therefore 
pregnancies at increased risk for adverse outcomes.17 More recently, criteria developed by the 
Australasian Diabetes in Pregnancy Society (ADIPS) have been widely used in Australia 
since 1991,18 and were updated and reviewed in 1998 (Table 1).1 In 2015 ADIPS adopted 
new diagnostic criteria as proposed by the International Association of Diabetes in Pregnancy 
Study Groups (IADPSG)17, and also introduced lower therapeutic targets (Table 1).18  
The catalyst for this change was the publication of the Hyperglycaemia and Adverse 
Pregnancy Outcomes (HAPO) Study in 2008.19 This multinational, blinded observational 
study of over 25 000 pregnant women found that there was a significantly increased risk of 
adverse pregnancy outcomes with elevated blood glucose levels below the threshold for 
diagnosis of GDM. Another study, the Australian Carbohydrate Intolerance Study in 
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Pregnant Women (ACHOIS) found lower rates of serious perinatal outcomes in the infants of 
women with milder degrees of glucose intolerance who were managed as GDM.20 
Subsequently, the IADPSG convened a multinational conference to review current evidence 
and develop evidence based diagnostic criteria.17 These criteria were introduced Australia 
wide in January 2015.21  
 
These guidelines were introduced with the aim of identifying more patients at risk of 
adverse outcomes in order to increase their glycaemic control, with the end goal of reducing 
the incidence of adverse pregnancy outcomes. With the introduction of new guidelines, it is 
important to evaluate if the predetermined goals were achieved, and to assess their impact. 
The aim of this study was to investigate how the new IADPSG criteria affect the diagnostic 
incidence and the incidence of therapeutic interventions. Our secondary aim was to compare 
the incidence of adverse pregnancy outcomes, including caesarean sections, macrosomia and 
mean birth weight.  
 
Materials and Methods 
This study was a retrospective clinical audit conducted at a regional hospital in 
Queensland which delivers approximately 1300 babies annually.22 Ethics was sought from 
Townsville Hospital and Health Service Human Research Ethics Committee and was 
endorsed as a quality review activity (HREC/15/QTHS/11). Data were collected for all 
pregnant women who delivered a singleton fetus between March and August 2014 (when 
1998 ADIPS diagnostic criteria used), and between March and August 2015 (when new 
IADPSG criteria used). An electronic system of medical record-keeping (iEMR), was used to 
access maternal demographic, pregnancy and birth data, in addition to neonatal 
demographics, birth details and perinatal outcome data. All data was collected and matched 
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with relevant glucose tolerance test (GTT) and glycated haemoglobin (HbA1c) results from 
the online pathology system. Multiple patient identifiers were used to ensure that the correct 
data was matched to the correct patient. 
 
Outcomes recorded were the incidence of diagnosis of GDM, and the treatment type 
used (diet alone, metformin, or insulin with or without metformin). The pregnancy outcomes 
analysed were the incidence of caesarean sections, incidence of macrosomia, and mean birth 
weight in the entire cohort. The mean HbA1c and the lowest mean fetal blood sugar level 
(BSL) were also recorded, only in patients with GDM.  
 
Ethics exemption was awarded with a waiver of participant consent by the Townsville 
Hospital and Health Service and James Cook University Human Research Ethics 
Committees. This project was registered as a quality activity with the hospital and Health 
Service Quality Improvement Unit.  
 
Statistics 
Statistical analysis was performed with the SPSS Statistics version 24 (IBM SPSS, 
Chicago, Illinois). Categorical variables were presented using descriptive analysis and 
frequencies. Relationships between change in guidelines and categorical variables were 
analysed with chi squared, or Mann Whitney U. Logistic regression was used to examine 
independent relationships. Our multivariate models for incidence of gestational diabetes, birth 
weight and method of delivery controlled for the independent variables of maternal body 
mass index (BMI), maternal ethnicity, diagnosis with GDM this pregnancy, baby gender and 





A sample size was calculated with power 80% and alpha 0.05. Our primary outcome 
was the incidence of GDM. We estimated that the local prevalence of GDM would be 7%,23 
and that with the new guidelines, based on predictive studies, it would increase to 10%.4, 24 




Of the 1390 women included in the study, 691 were assessed as GDM using the 1998 
ADIPS criteria from March to August 2014, and 699 women were assessed using the new 
IADPSG criteria from March to August 2015. 
 
Maternal Characteristics 
Maternal demographic characteristics are summarised in Table 2. These 
characteristics were comparable at baseline. 
 
Incidence of GDM Diagnosis 
There was a statistically significant increase in the incidence of diagnosis with GDM 
with the new IADPSG diagnostic criteria (19.6% vs 9.8%, p<0.01) (Table 3).   
 
Treatment of GDM 
There was an increase in the proportion of patients with GDM treated with metformin 
(24.8% vs 17.7%), and insulin (26.3% vs 19.1%). As there was a doubling in the number of 
women diagnosed with GDM, this equated to an even greater increase in the proportion of the 
population treated – almost three times as many women were on metformin, insulin and 
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metformin or insulin alone with the change in diagnostic and therapeutic targets (Table 4). 
This finding was statistically significant when the proportion of the population treated was 
used as the denominator. The proportion of women with GDM controlled with diet was lower 




There was a statistically significant decrease in mean HbA1c under the new IADPSG 
guidelines (5.3% [33.3mmol/mol] vs 5.2% [32.2mmol/mol], p=0.03) (Table 5). This was 
calculated on data recorded for 60 or the 68 diagnosed cases of GDM under the ADIPS 
guidelines and 118 of the 137 diagnosed cases of GDM under the new guidelines.  
 
Adverse Pregnancy Outcomes 
Adverse pregnancy outcomes in the two patient cohorts are summarised in Table 3.  
 
Method of Delivery 
There was an increase in the number of emergency caesarean sections with the new 
IADPSG guidelines, although this was not statistically significant (13.6% vs 15.9%, p = 
0.26). There was a decrease in instrumental deliveries with new IADPSG guidelines which 
was significant on univariate but not multivariate analysis (12.9% vs 8.9%, p = 0.02).  The 
data for spontaneous vaginal deliveries and elective caesarean sections were similar before 








There was no statistically significant difference in the number of neonates with 
macrosomia in the overall patient cohorts (i.e. patients with or without GDM) between the 
two study groups (1.9% vs 2.0%, p = 1.00). We were underpowered to conduct multivariate 
analysis for this outcome. 
 
Mean Birth Weight 
Mean birth weight was slightly higher under the IADPSG guidelines compared to the 
ADIPS guidelines (3415.1g vs 3367.7g). This was not significant on univariate or 
multivariate analysis.  
 
Neonatal hypoglycaemia 
The lowest blood sugar level recorded while in hospital was used as a marker of 
neonatal hypoglycaemia. This was significantly higher (p=0.03) following the change in 




This study found that the implementation of the new IADPSG guidelines resulted in 
doubling the incidence of gestational diabetes from 9.8% to 19.6% over the time period 
measured. The incidence of GDM was on the upper limit of the national range prior to the 




Although mean maternal HbA1c decreased with the new guidelines, the 
measurements before and after the change in guidelines are not comparable, as a larger 
proportion of the pregnant population, and therefore a larger number of women who were 
likely to have milder glucose intolerance, were diagnosed with GDM following the change in 
guidelines. Similarly, it is not possible to directly compare the mean recorded neonatal BSL, 
which is only measured in the children of mothers with GDM. It is likely that the difference 
may simply reflect that over 50% of neonates following the change of guidelines had mothers 
with milder degrees of glucose intolerance. We therefore feel that it is important that the 
success of the new guidelines should not be based on the comparison of the outcomes of the 
cohorts of patients diagnosed with GDM, as these outcomes will inevitably be favourable 
under the new guidelines. Despite the increase in the incidence of diagnosis of GDM and 
therefore likely milder degree of glucose intolerance, there was a trend towards an increase in 
the number of women treated with metformin, or insulin with or without metformin following 
the change in guidelines. When this change in management was examined using the entire 
patient cohort as the denominator, therefore reflecting the increased workload, this increase in 
pharmacological treatments became statistically significant, with close to three times as many 
patients prescribed insulin, insulin and metformin or metformin alone. These differences 
could be attributed to a change in the therapeutic as well as diagnostic criteria.  
The data reveals no significant reduction in the adverse pregnancy outcomes that were 
measured: caesarean section, macrosomia and mean birth weight. There are some limitations 
to the interpretation of this finding. As 50% of diagnoses of GDM under the new guidelines 
are likely to have a milder degree of glucose dysfunction, it is not appropriate to use GDM as 
the denominator. However, by using the entire cohort as the denominator, the effect of the 
new guidelines on adverse outcomes is diluted by the 80% of patients who were not 
diagnosed with GDM. Consequently, we are also underpowered to make this comparison. 
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The most appropriate method of assessing the change in guidelines would be to compare the 
group of patients in the 2015 cohort who would have been diagnosed with GDM using the 
new diagnostic criteria, but were managed as non GDM patients, with patients in 2016 who 
would not have been diagnosed under the old criteria but were diagnosed and managed as 
GDM under the new criteria. Unfortunately this comparison is unable to be made, first 
because of incomplete data sets and second because 75g oral glucose tolerance testing was 
not routinely performed in 2015. (In 2015 pregnant women had a 75g oral glucose tolerance 
test if they had risk factors for GDM or a positive result on a 50g oral glucose challenge 
test.)15 Equally it would be valid to compare the additional cases identified with IADPSG 
with those who would have been identified with by ADIPS in the second cohort, but the 
comparisons cannot be made for the same reasons.  
 
Secondary analysis of data from patient cohorts prior to the change in guidelines had 
shown that the incidence of diagnosis increased from 9.6 to 13.0% 4 and 13% to 16%, 24 when 
the new guidelines were theoretically applied retrospectively. However our increase in 
incidence was far greater than this predicted increase. Prior to the change in guidelines, 
statistical modelling had also shown that the subgroup of patients who were not diagnosed 
with old guidelines, but fitted the diagnostic criteria of the new guidelines had neonates 
which were on average 106g heavier and had a significantly higher incidence of 
macrosomia.3, 24 Despite these findings, our study did not find any difference in neonatal 
outcomes.  
 
We were unable to identify any Australian studies in the literature which compare 
pregnancy outcomes in patient cohorts before and after the introduction of the IADPSG 
criteria. A Belgian study found that introduction of the IADPSG guidelines, compared with 
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previous ‘Carpenter and Coustan criteria’25 increased the incidence of GDM (from 8 to 23%) 
but did not decrease the incidence of macrosomia or LSCS.26 Similarly, a Swiss study found 
a four-fold increase in incidence of diagnosis from (3.3% to 11.8%) with the introduction in 
the IADPSG criteria.27 
 
We must acknowledge some limitations of our study. There was a lower incidence of 
both LSCS and macrosomia that was expected and we may have been underpowered to 
measure a true difference. The study is limited by examining short term outcomes in a single 
centre. Longer term studies or studies in other settings may show more benefit.    
 
Inevitably, an increase of incidence of diagnosis, as well as the increase in therapeutic 
interventions will result in a significantly increased workload, and consequent increased 
health care costs.  Despite this increased workload our study did not show any reduction in 
adverse outcomes.  
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